Intravenous versus subcutaneous immunoglobulin - Authors' reply
- PMID: 29656738
- DOI: 10.1016/S1474-4422(18)30109-1
Intravenous versus subcutaneous immunoglobulin - Authors' reply
Comment on
-
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Clinical Trial.
-
Intravenous versus subcutaneous immunoglobulin.Lancet Neurol. 2018 May;17(5):393. doi: 10.1016/S1474-4422(18)30106-6. Lancet Neurol. 2018. PMID: 29656737 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources